Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Detailed price information for American Tower Corp (AMT-N) from The Globe and Mail including charting and trades.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.